Alpha 2.0
Login Register
» Authors » Guangbin Peng

Guangbin Peng

Explore the profile of Guangbin Peng including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 19
Citations 303
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
Neurology
Top 10 Co-Authors
Coleman K Obasaju
Matthew J Monberg
Coleman Obasaju
Mark A Socinski
Joseph Treat
Deborah Lee
Frank C Detterbeck
Matthew Monberg
Lina Asmar
Yu Qiao
Published In
Clin Lung Cancer
J Clin Oncol
Lung Cancer
J Thorac Oncol
Epilepsia
Affiliations
Soon will be listed here.
Recent Articles
1.
Moxibustion alleviates intestinal inflammation in ulcerative colitis rats by modulating long non-coding RNA LOC108352929 and inhibiting Phf11 expression
Li G, Zhao C, Xu J, Huang Y, Qiao Y, Li F, et al.
Heliyon . 2024 Mar; 10(5):e26898. PMID: 38439851
Long noncoding RNA (lncRNAs) are involved in the pathogenesis of ulcerative colitis (UC). Moxibustion, a traditional Chinese medicine, can improve symptoms in patients with UC and reduce intestinal inflammation in...
2.
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Hong D, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen E, et al.
Clin Cancer Res . 2023 Mar; 29(12):2210-2219. PMID: 37000164
Purpose: Eganelisib (IPI-549) is a first-in-class, orally administered, highly selective PI3Kγ inhibitor with antitumor activity alone and in combination with programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitors in preclinical...
3.
Acupuncture for Fibromyalgia: A Review Based on Multidimensional Evidence
Han D, Lu Y, Huang R, Yang Z, Peng G, Qiao Y, et al.
Am J Chin Med . 2023 Jan; 51(2):249-277. PMID: 36599648
Fibromyalgia (FM) is a complicated syndrome characterized by widespread chronic pain, fatigue, sleep disturbances, cognitive dysfunction, and other complications. There is currently no specific treatment available. No comprehensive surveys have...
4.
Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study
Gidal B, Wechsler R, Sankar R, Montouris G, White H, Cloyd J, et al.
Neurology . 2016 Sep; 87(17):1806-1812. PMID: 27683846
Objective: To evaluate potential development of tolerance to adjunctive clobazam in patients with Lennox-Gastaut syndrome. Methods: Eligible patients enrolled in open-label extension study OV-1004, which continued until clobazam was commercially...
5.
Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012
Isojarvi J, Lee D, Peng G, Sperling M
Epilepsia . 2016 May; 57(6):e113-6. PMID: 27145465
Drop seizures are especially problematic in patients with Lennox-Gastaut syndrome (LGS) because of their potential for serious injury. In this post hoc analysis of phase 3 OV-1012 data, a medical...
6.
Intravenous carbamazepine as short-term replacement therapy for oral carbamazepine in adults with epilepsy: Pooled tolerability results from two open-label trials
Lee D, Kalu U, Halford J, Biton V, Cloyd J, Klein P, et al.
Epilepsia . 2015 Apr; 56(6):906-14. PMID: 25912051
Objective: To report tolerability findings and maintenance of seizure control from a pooled analysis of phase I open-label trial OV-1015 (NCT01079351) and phase III study 13181A (NCT01128959). Methods: Patients receiving...
7.
An exploratory subgroup analysis of race and gender in squamous cancer of the head and neck: inferior outcomes for African American males in the LORHAN database
Hayes D, Peng G, Pennella E, Hossain A, Cuyun Carter G, Muehlenbein C, et al.
Oral Oncol . 2014 Mar; 50(6):605-10. PMID: 24637172
Objectives: Previous retrospective analyses show poor outcomes for African American (AA) patients with head and neck carcinoma (HNC). Such racial disparities are not well understood, and generally studies have been...
8.
Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer
Choy H, Schwartzberg L, Dakhil S, Garon E, Gerber D, Choksi J, et al.
J Thorac Oncol . 2013 Aug; 8(10):1308-16. PMID: 23981966
Introduction: There is no consensus chemotherapy regimen with concurrent radiotherapy (RT) for inoperable stage IIIA/B non-small-cell lung cancer. This trial evaluated pemetrexed with carboplatin (PCb) or cisplatin (PC) with concurrent...
9.
Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer
Ahn M, Yang J, Liang J, Kang J, Xiu Q, Chen Y, et al.
Lung Cancer . 2012 Apr; 77(2):346-52. PMID: 22534669
Introduction: Treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors or chemotherapy have shown improved survival outcomes in East Asian, never-smoker patients with non-small cell lung cancer (NSCLC). However, treatment...
10.
Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials
Treat J, Scagliotti G, Peng G, Monberg M, Obasaju C, Socinski M
Lung Cancer . 2011 Nov; 76(2):222-7. PMID: 22115704
Introduction: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005),...